ACCESS BIOTECHNOLOGY
Access Biotechnology is the life science investment arm of Access Industries. They invest in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. They invest in both private and public biopharma companies across therapeutic areas, modalities, and development stages – from discovery-stage technology platforms to late-stage clinical programs. The company is based in New York.
ACCESS BIOTECHNOLOGY
Social Links:
Industry:
Biopharma Biotechnology Health Care Life Science
Founded:
1986-01-01
Status:
Active
Contact:
(212) 247-6400
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Apache Sitelinks Search Box Yoast WordPress SEO Plugin Yoast SEO Premium Yoast Plugins PHP
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
PCI Pharma Services
PCI Pharma Services is a provider of outsourced services to the global pharmaceutical market.
Penn Medicine Co-Investment Program
Penn Medicine Co-Investment Program makes investments in faculty-driven cell therapy, gene therapy, and connected health companies
Current Employees Featured
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-10 | Disc Medicine | Access Biotechnology investment in Venture Round - Disc Medicine | N/A |
| 2022-07-12 | Areteia Therapeutics | Access Biotechnology investment in Series A - Areteia Therapeutics | 350 M USD |
| 2022-06-02 | Upstream Bio | Access Biotechnology investment in Series A - Upstream Bio | 200 M USD |
| 2021-12-01 | Curie Therapeutics | Access Biotechnology investment in Series A - Curie Therapeutics | 75 M USD |
| 2021-11-15 | Recludix Pharma | Access Biotechnology investment in Series A - Recludix Pharma | 60 M USD |
| 2021-09-02 | Disc Medicine | Access Biotechnology investment in Series B - Disc Medicine | 90 M USD |
| 2021-07-13 | Nimbus Therapeutics | Access Biotechnology investment in Venture Round - Nimbus Therapeutics | 105 M USD |
| 2021-05-24 | Eliem Therapeutics | Access Biotechnology investment in Series B - Eliem Therapeutics | 60 M USD |
| 2021-03-25 | Eliem Therapeutics | Access Biotechnology investment in Series A - Eliem Therapeutics | 80 M USD |
| 2021-03-01 | DTx Pharma | Access Biotechnology investment in Series B - DTx Pharma | 100 M USD |
More informations about "Access Biotechnology"
Biotechnology - Access Industries
Access Biotechnology invests in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. Our approach is …See details»
Access Biotechnology - CB Insights
Feb 5, 2024 About Access Biotechnology Access Biotechnology is the biopharma investment arm of Access Industries, a U.S.-based private holding company and investment firm. Access …See details»
Access Biotechnology - Investments, Portfolio & Company Exits
Access Biotechnology has made 8 diversity investments. Their most recent diversity investment was on Jul 30, 2024 , when Day One Biopharmaceuticals raised obfuscatedSee details»
Access Biotechnology investment portfolio - PitchBook
Access Biotechnology's latest investment was on 31-Jul-2024 in Halda Therapeutics, a company within the Drug Discovery industry. Data Transparency. Meet our data hygiene team. Discover how our experts ensure you’re getting …See details»
Access Biotechnology Inc - Company Profile and News
Access Biotechnology Inc operates as an investment firm. The Company invests in both private and public biopharma companies across therapeutic areas, modalities, and development …See details»
Access Biotechnology - Investor Profile, Portfolio & Team - Tracxn
Oct 22, 2024 Co-investors of Access Biotechnology. Over the past . 5 years, 138 investors have co-invested in Access Biotechnology's portfolio companies.. This includes funds and …See details»
Access Biotechnology - raizer.app
Access Biotechnology is an investment arm of Access Industries that focuses on private and public biopharma companies. Learn which startups Access Biotechnology invests in, number …See details»
Access Biotechnology - Updates, News, Events, Signals & Triggers
Access Biotechnology is an investment arm of Access Industries that focuses on private and public biopharma companies. Search Crunchbase. Start Free Trial . Chrome Extension. …See details»
Access Biotechnology (investor) - Nordic 9
Access Biotechnology (investor). Access Biotechnology is an investment arm of Access Industries that focuses on private and public biopharma companies across therapeutic areas, modalities, …See details»
GRO Biosciences Closes $60M Series B Financing Co …
Jul 19, 2024 Access Biotechnology is the biopharma investment arm of Access Industries, a U.S.-based private holding company and investment firm. Access invests in private and public companies developing transformative therapies …See details»
Dan Becker - Access Industries
Dan Becker joined Access Biotechnology in August 2019. Prior to Access, Dan was a Principal at New Leaf Venture Partners, where he played a key role in multiple private and public …See details»
Biotechnology Innovation Organization | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... to patients with serious …See details»
American Biotechnology Association
We value access to education and sustainable supports to empower communities through mastery of biotechnology skills sets. Our Mission American Biotechnology Association, Inc. …See details»
Access Biotechnology - Contacts, Employees, Board Members
Access Biotechnology has 4 current employee profiles, including Principal Dan Becker. Dan Becker Principal. Christine Borowski Senior Associate. Liam Ratcliffe Head of Biotechnology. …See details»
New BIO Report Finds More Innovation & Investment Needed in …
Jan 25, 2024 Today, the Biotechnology Innovation Organization (BIO) released a new report, "The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases," …See details»
BIO’s plan to promote opportunity and access for the underserved …
Sep 11, 2020 Promote access to vaccines and therapeutics for uninsured and underserved populations, especially related to COVID-19 ... M.M.-H. works for industry trade organization …See details»
The need for global access to biomedical innovations during
May 24, 2021 Nature Biotechnology - The need for global access to biomedical innovations during pandemics. ... Expanding Access to Monoclonal Antibody-Based Products: ... (World …See details»
Dan Becker - Principal @ Access Biotechnology - Crunchbase
Dan Becker joined New Leaf Venture Partners in 2015. Prior to joining New Leaf, Dan was a Principal at the Boston Consulting Group where he was a core member of their Health Care …See details»
Expanding global access to genetic therapies | Nature Biotechnology
Jan 7, 2022 The resultant price drop has given ARV access to more than 5 million people in the developing world 11. It is reasonable to assume that a similar model can be applied to genetic …See details»